{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T11:26:36Z","timestamp":1794309996964,"version":"4.9.0"},"reference-count":100,"publisher":"Informa UK Limited","issue":"11","funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["U01DK048377"],"award-info":[{"award-number":["U01DK048377"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Opinion on Pharmacotherapy"],"published-print":{"date-parts":[[2020,7,23]]},"DOI":"10.1080\/14656566.2020.1748599","type":"journal-article","created":{"date-parts":[[2020,4,15]],"date-time":"2020-04-15T10:03:17Z","timestamp":1586944997000},"page":"1319-1328","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":54,"title":["The limits and challenges of antiobesity pharmacotherapy"],"prefix":"10.1080","volume":"21","author":[{"given":"Kishore M","family":"Gadde","sequence":"first","affiliation":[{"name":"Pennington Biomedical Research Center, Baton Rouge, LA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katelyn D","family":"Atkins","sequence":"additional","affiliation":[{"name":"Pennington Biomedical Research Center, Baton Rouge, LA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2020,4,15]]},"reference":[{"key":"cit0001","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1614362"},{"key":"cit0002","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2017.11.011"},{"key":"cit0003","doi-asserted-by":"publisher","DOI":"10.1210\/er.2017-00253"},{"key":"cit0004","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.g2646"},{"key":"cit0005","doi-asserted-by":"publisher","DOI":"10.1002\/oby.21454"},{"key":"cit0006","doi-asserted-by":"publisher","DOI":"10.1016\/j.jneb.2018.08.015"},{"key":"cit0007","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2017.12.014"},{"key":"cit0008","doi-asserted-by":"publisher","DOI":"10.1373\/clinchem.2017.272815"},{"key":"cit0009","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-143-5-200509060-00013"},{"key":"cit0010","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.1992.76"},{"key":"cit0011","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.163.9.1046"},{"key":"cit0012","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.111.028381"},{"key":"cit0013","volume-title":"Draft guidance clinical evaluation of weight control drug","author":"Food and Drug Administration","year":"1996"},{"key":"cit0014","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199809103391102"},{"key":"cit0015","unstructured":"Food and Drug Administration. Guidance for industry: developing products for weight management, draft guidance, revision 1. Center for Drug Evaluation and Research (CDER), FDA, Rockville, MD. 2007. [Cited 2020 Mar 18]. Available from: https:\/\/www.fda.gov\/media\/71252\/download"},{"key":"cit0016","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.105.596130"},{"key":"cit0017","unstructured":"European Medicines Agency. Press release: the european medicines agency recommends the suspension of the marketing authorisation of acomplia. Doc. Ref. EMEA\/CHMP537777\/2008 London, 23 October 2008. [Cited 2020 Mar 18]. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/press-release\/european-medicines-agency-recommends-suspension-marketing-authorisation-acomplia_en.pdf"},{"key":"cit0018","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1003114"},{"key":"cit0019","doi-asserted-by":"publisher","DOI":"10.1159\/000488880"},{"key":"cit0020","doi-asserted-by":"publisher","DOI":"10.1002\/oby.21136"},{"key":"cit0021","doi-asserted-by":"publisher","DOI":"10.1002\/oby.21533"},{"key":"cit0022","unstructured":"U.S. Government Accountability Office. Obesity drugs: few adults used prescription drugs for weight loss and insurance coverage varied GAO-19-577, Aug 2019. [Cited 2020 Mar 18]. Available from: https:\/\/www.gao.gov\/products\/GAO-19-577"},{"key":"cit0023","doi-asserted-by":"publisher","DOI":"10.1002\/oby.20584"},{"key":"cit0024","volume-title":"In: Presentation before the Science Board to the Food and Drug Administration April 2004","author":"Orloff D"},{"key":"cit0025","doi-asserted-by":"publisher","DOI":"10.1002\/oby.22430"},{"key":"cit0026","doi-asserted-by":"publisher","DOI":"10.1002\/oby.22516"},{"key":"cit0027","doi-asserted-by":"publisher","DOI":"10.1517\/14656566.2014.890590"},{"key":"cit0028","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1712231"},{"key":"cit0029","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2016.7602"},{"key":"cit0030","unstructured":"U.S. Food and Drug Administration. Drug safety communications. FDA requests the withdrawal of the weight-loss drug belviq, belviq XR (lorcaserin) from the market. Potential risk of cancer outweighs the benefits. [Cited 2020 Mar 18]. Available from: https:\/\/www.fda.gov\/media\/135189\/download"},{"key":"cit0031","doi-asserted-by":"publisher","DOI":"10.1007\/s11892-017-0859-2"},{"key":"cit0032","doi-asserted-by":"publisher","DOI":"10.1002\/oby.20761"},{"key":"cit0033","doi-asserted-by":"publisher","DOI":"10.1111\/dom.12971"},{"key":"cit0034","first-page":"CD007654","volume":"3","author":"Siebenhofer A","year":"2016","journal-title":"Cochrane Database Syst Rev"},{"key":"cit0035","unstructured":"Food and drug administration. FDA briefing document: NDA 200063: contrave (Naltrexone 4mg, 8 mg\/Bupropion HCL 90 mg extended release tablet). Advisory committee - December 7, 2010. [Cited 2020 Mar 18]. Available from: https:\/\/wayb`.archive-it.org\/7993\/20170405220555\/https:\/\/www.fda.gov\/downloads\/AdvisoryCommittees\/CommitteesMeetingMaterials\/Drugs\/EndocrinologicandMetabolicDrugsAdvisoryCommittee\/UCM235671.pdf"},{"key":"cit0036","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2016.1558"},{"key":"cit0037","unstructured":"Herper M The FDA is forcing Orexigen to do a second safety study because of contrave disclosures. Forbes Business News, 3 March 2015. [Cited 2020 Mar 18]. Available from: https:\/\/www.forbes.com\/sites\/matthewherper\/2015\/03\/03\/the-fda-will-force-orexigen-to-do-a-second-safety-study-because-of-contrave-disclosures\/#7505ad1b4e98"},{"key":"cit0038","unstructured":"Husten L Orexigen terminates another cardiovascular outcomes trial. CardioBrief, 13 April. 2016. [Cited 2020 Mar 18]. Available from: http:\/\/www.cardiobrief.org\/2016\/04\/13\/orexigen-terminates-another-cardiovascular-outcomes-trial\/"},{"key":"cit0039","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(15)00803-X"},{"key":"cit0040","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1603827"},{"key":"cit0041","unstructured":"Food and Drug Administration. NDA022580 approval letter to Vivus 17 July 2012. [Cited 2020 Mar 18]. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/appletter\/2012\/022580Origs000ltr.pdf"},{"key":"cit0042","doi-asserted-by":"publisher","DOI":"10.1517\/14656560902824152"},{"key":"cit0043","first-page":"A17","volume":"14","author":"Gadde KM","year":"2006","journal-title":"Obes Res"},{"key":"cit0044","doi-asserted-by":"publisher","DOI":"10.1038\/oby.2008.461"},{"key":"cit0045","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2009-1350"},{"key":"cit0046","doi-asserted-by":"publisher","DOI":"10.1038\/oby.2002.86"},{"key":"cit0047","doi-asserted-by":"publisher","DOI":"10.1038\/oby.2002.142"},{"key":"cit0048","doi-asserted-by":"publisher","DOI":"10.1097\/MED.0b013e3283304f90"},{"key":"cit0049","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2019.14725"},{"key":"cit0050","doi-asserted-by":"publisher","DOI":"10.1001\/jama.293.23.2873"},{"key":"cit0051","unstructured":"Vivus, Inc. ClinicalTrials.gov Identifier: NCT02714062. A pharmacokinetic study comparing VI-0521 with placebo in obese adolescents. [Cited 2020 Mar 18]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/results\/NCT02714062"},{"key":"cit0052","unstructured":"Vivus, Inc. ClinicalTrials.gov Identifier: NCT03922945. A phase IV safety and efficacy of VI-0521 in obese adolescents. [Cited 2020 Mar 18]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03922945"},{"key":"cit0053","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1916038"},{"key":"cit0054","doi-asserted-by":"publisher","DOI":"10.1097\/00006842-199805000-00021"},{"key":"cit0055","doi-asserted-by":"publisher","DOI":"10.1002\/j.1550-8528.1999.tb00436.x"},{"key":"cit0056","doi-asserted-by":"publisher","DOI":"10.1007\/s11605-007-0427-1"},{"key":"cit0057","doi-asserted-by":"publisher","DOI":"10.1001\/archsurg.138.5.541"},{"key":"cit0058","doi-asserted-by":"publisher","DOI":"10.1007\/s11695-015-1979-x"},{"key":"cit0059","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa035622"},{"key":"cit0060","doi-asserted-by":"publisher","DOI":"10.1016\/j.soard.2011.04.231"},{"key":"cit0061","doi-asserted-by":"publisher","DOI":"10.1007\/s11695-015-1611-0"},{"key":"cit0062","doi-asserted-by":"publisher","DOI":"10.1007\/s11695-016-2125-0"},{"key":"cit0063","doi-asserted-by":"publisher","DOI":"10.1007\/s11695-016-2337-3"},{"key":"cit0064","doi-asserted-by":"publisher","DOI":"10.1590\/S0100-69912013000300005"},{"key":"cit0065","doi-asserted-by":"publisher","DOI":"10.1016\/j.soard.2016.10.018"},{"key":"cit0066","doi-asserted-by":"publisher","DOI":"10.1016\/j.soard.2017.10.002"},{"key":"cit0067","doi-asserted-by":"publisher","DOI":"10.1007\/s11695-018-3141-z"},{"key":"cit0068","doi-asserted-by":"publisher","DOI":"10.1007\/s11695-018-3393-7"},{"key":"cit0069","doi-asserted-by":"publisher","DOI":"10.1111\/cob.12323"},{"key":"cit0070","doi-asserted-by":"publisher","DOI":"10.1381\/096089296765556476"},{"key":"cit0071","doi-asserted-by":"publisher","DOI":"10.1381\/0960892041590926"},{"key":"cit0072","doi-asserted-by":"publisher","DOI":"10.1089\/bari.2018.0037"},{"key":"cit0073","doi-asserted-by":"publisher","DOI":"10.3390\/children5090116"},{"key":"cit0074","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0909809"},{"key":"cit0075","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(10)60888-4"},{"key":"cit0076","doi-asserted-by":"publisher","DOI":"10.1038\/oby.2011.330"},{"key":"cit0077","doi-asserted-by":"publisher","DOI":"10.1038\/oby.2010.147"},{"key":"cit0078","doi-asserted-by":"publisher","DOI":"10.1001\/jama.295.7.826"},{"key":"cit0079","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0006624"},{"key":"cit0080","doi-asserted-by":"publisher","DOI":"10.1001\/2013.jamainternmed.99"},{"key":"cit0081","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.81.5.1498"},{"key":"cit0082","doi-asserted-by":"publisher","DOI":"10.1093\/oxfordjournals.aje.a116280"},{"key":"cit0083","volume-title":"Prescribing information for Xenical (orlistat) capsules","year":"2017"},{"key":"cit0084","doi-asserted-by":"publisher","DOI":"10.2337\/diacare.27.1.155"},{"key":"cit0085","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)30069-7"},{"key":"cit0086","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(11)60205-5"},{"key":"cit0087","unstructured":"ClinicalTrials.gov Identifier NCT 00796367. A safety and efficacy study of VI-0521 to evaluate the long-term treatment of obesity in adults with obesity-related comorbid conditions. An extension of protocol OB-303 (NCT00553787). Cited 2020 Mar 18. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/results\/NCT00796367?term=vivus"},{"key":"cit0088","unstructured":"European Medicines Agency. Refusal of the marketing authorisation for Qsiva (phentermine\/topiramate): outcome of re-examination. European Medicines Agency London, UK 21 February 2013. Cited 2020 Mar 18. Available from: http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Summary_of_opinion_-_Initial_authorisation\/human\/002350\/WC500139215.pdf"},{"key":"cit0089","unstructured":"National Institute for Health and Care Excellence. Naltrexone-Bupropion for managing overweight and obesity. Technology appraisal guidance [TA494] 12 December 2017. Cited 2020 Mar 18. Available from: https:\/\/www.nice.org.uk\/guidance\/ta494\/resources\/naltrexonebupropion-for-managing-overweight-and-obesity-pdf-82605086955205"},{"key":"cit0090","unstructured":"Vivus, Inc. Qsymia (phentermine and topiramate extended-release) Capsules: risk evaluation and mitigation strategy (REMS). Cited 2020 Mar 18. Available from: https:\/\/www.qsymiarems.com\/"},{"key":"cit0091","doi-asserted-by":"crossref","unstructured":"Thomas DD, Waring ME, Ameli O, et al. Patient characteristics associated with receipt of prescription weight\u2010management medications among veterans participating in MOVE! Obesity. 2019;27:1168\u20131176.","DOI":"10.1002\/oby.22503"},{"key":"cit0092","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2018.07.017"},{"key":"cit0093","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2018.7777"},{"key":"cit0094","doi-asserted-by":"publisher","DOI":"10.4158\/EP-2017-0221"},{"key":"cit0095","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1109220"},{"key":"cit0096","doi-asserted-by":"publisher","DOI":"10.1111\/head.13281"},{"key":"cit0097","volume-title":"Prescribing information for Vyvanse (lisdexamfetamine dimesylate) capsules, CII","year":"2018"},{"key":"cit0098","doi-asserted-by":"publisher","DOI":"10.1038\/sj.ijo.0801699"},{"key":"cit0099","doi-asserted-by":"publisher","DOI":"10.1016\/j.jash.2017.12.002"},{"key":"cit0100","doi-asserted-by":"publisher","DOI":"10.1007\/s11906-019-0915-1"}],"container-title":["Expert Opinion on Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/14656566.2020.1748599","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,8]],"date-time":"2021-05-08T09:28:24Z","timestamp":1620466104000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/14656566.2020.1748599"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4,15]]},"references-count":100,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2020,7,23]]}},"alternative-id":["10.1080\/14656566.2020.1748599"],"URL":"https:\/\/doi.org\/10.1080\/14656566.2020.1748599","relation":{},"ISSN":["1465-6566","1744-7666"],"issn-type":[{"value":"1465-6566","type":"print"},{"value":"1744-7666","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,4,15]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ieop20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ieop20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2019-12-16","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-03-25","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-04-15","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}